Boston Common Asset Management LLC Raises Holdings in Eli Lilly and Company $LLY

Boston Common Asset Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 31.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 35,763 shares of the company’s stock after acquiring an additional 8,468 shares during the period. Boston Common Asset Management LLC’s holdings in Eli Lilly and Company were worth $27,878,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of LLY. PNC Financial Services Group Inc. increased its holdings in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after acquiring an additional 682,203 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.5%

Eli Lilly and Company stock opened at $840.46 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The stock has a 50 day moving average of $734.60 and a two-hundred day moving average of $765.98. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $795.47 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm earned $3.92 EPS. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LLY shares. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $938.94.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.